• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球消除 HCV——为什么波兰仍如此之远?

Global Elimination of HCV-Why Is Poland Still So Far from the Goal?

机构信息

Department of Transplantation Medicine, Nephrology, and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, Poland.

Department of Education and Research in Health Sciences, Faculty of Health Sciences, Medical University of Warsaw, 02-091 Warsaw, Poland.

出版信息

Viruses. 2023 Oct 9;15(10):2067. doi: 10.3390/v15102067.

DOI:10.3390/v15102067
PMID:37896844
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10612042/
Abstract

INTRODUCTION

Eradication of HCV in the global population remains one of the greatest challenges faced by the WHO. An insufficient level of knowledge and the lack of a national screening test strategy are obstacles to HCV eradication.

AIM

This work aimed to summarize surveys assessing risk factors and awareness of the respondents regarding the prevention and course of HCV infection. The summary also includes the most important European and global attempts at eliminating HCV.

MATERIALS AND METHODS

A cross-sectional, population-based study was conducted in the Mazowieckie district in Poland using anonymous surveys and conducted on people who willingly reported for a test.

RESULTS

In the study cohort of n = 7397 adults, there were 5412 women (73.16%). The analysis of the quota sample ( = 1303) reflected the actual proportions in the population of the Mazowieckie Voivodeship.

CONCLUSIONS

Insufficient knowledge about HCV decreases the probability of higher detection of infections, fast diagnostics, and treatment. According to the WHO model, assuming a 90% detection rate and treatment of 80% of infected by 2030, and taking into account 120-150 thousand infected persons in Poland, the number of detections of HCV should be increased 4-5 times and all diagnosed persons should be offered antiviral treatment.

摘要

简介

在全球范围内消除 HCV 仍然是世卫组织面临的最大挑战之一。知识水平不足和缺乏国家筛查测试策略是 HCV 消除的障碍。

目的

这项工作旨在总结评估风险因素和受访者对 HCV 感染预防和病程的认识的调查。摘要还包括欧洲和全球消除 HCV 的最重要尝试。

材料和方法

在波兰马佐夫舍省进行了一项横断面、基于人群的研究,使用匿名调查并对自愿接受检测的人进行。

结果

在研究队列的 7397 名成年人中,有 5412 名女性(73.16%)。配额样本(n = 1303)的分析反映了马佐夫舍省人口的实际比例。

结论

对 HCV 的了解不足会降低更高检出感染、快速诊断和治疗的可能性。根据世卫组织的模型,假设到 2030 年,感染率提高 90%,80%的感染者接受治疗,考虑到波兰有 12 至 15 万感染者,应该将 HCV 的检出率提高 4-5 倍,并为所有确诊患者提供抗病毒治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30d/10612042/11ab7f1e35c1/viruses-15-02067-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30d/10612042/200a9faf1671/viruses-15-02067-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30d/10612042/7153ddfe2eab/viruses-15-02067-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30d/10612042/55700c6698a5/viruses-15-02067-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30d/10612042/579307eb137e/viruses-15-02067-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30d/10612042/11ab7f1e35c1/viruses-15-02067-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30d/10612042/200a9faf1671/viruses-15-02067-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30d/10612042/7153ddfe2eab/viruses-15-02067-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30d/10612042/55700c6698a5/viruses-15-02067-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30d/10612042/579307eb137e/viruses-15-02067-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30d/10612042/11ab7f1e35c1/viruses-15-02067-g005.jpg

相似文献

1
Global Elimination of HCV-Why Is Poland Still So Far from the Goal?全球消除 HCV——为什么波兰仍如此之远?
Viruses. 2023 Oct 9;15(10):2067. doi: 10.3390/v15102067.
2
Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study.冰岛治疗即预防丙型肝炎(TraP HepC)项目中前 36 个月的治疗流程:一项基于人群的研究。
Lancet Gastroenterol Hepatol. 2021 Aug;6(8):628-637. doi: 10.1016/S2468-1253(21)00137-0. Epub 2021 Jun 23.
3
The problem of elimination of HCV infections in Poland.波兰丙型肝炎病毒感染的消除问题。
Przegl Epidemiol. 2017;71(1):3-14.
4
Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?针对直接作用抗病毒药物的定制筛查和专项经费:如何保持意大利在丙型肝炎病毒消除的道路上?
Ann Ist Super Sanita. 2020 Jul-Sep;56(3):325-329. doi: 10.4415/ANN_20_03_10.
5
Hepatitis C in Poland in 2020.2020 年波兰的丙型肝炎。
Przegl Epidemiol. 2022;76(2):233-242. doi: 10.32394/pe.76.23.
6
Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.在澳大利亚,直接作用抗病毒疗法可无限制获取之前和之后,注射吸毒者中丙型肝炎病毒原发性感染的发生率。
Addiction. 2023 May;118(5):901-911. doi: 10.1111/add.16113. Epub 2022 Dec 29.
7
Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.在可负担得起的直接抗病毒药物时代,希腊丙型肝炎消除策略的经济评估。
World J Gastroenterol. 2019 Mar 21;25(11):1327-1340. doi: 10.3748/wjg.v25.i11.1327.
8
Reduced incidence of hepatitis C in 9 villages in rural Egypt: Progress towards national elimination goals.埃及农村 9 个村庄丙型肝炎发病率降低:迈向国家消除目标的进展。
J Hepatol. 2021 Feb;74(2):303-311. doi: 10.1016/j.jhep.2020.09.008. Epub 2020 Sep 12.
9
French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long.法国丙型肝炎护理链:直接作用抗病毒药物影响巨大,但消除之路仍漫长。
BMC Infect Dis. 2020 Oct 15;20(1):759. doi: 10.1186/s12879-020-05478-6.
10
Burden of pediatric hepatitis C.儿童丙型肝炎负担。
World J Gastroenterol. 2013 Nov 28;19(44):7880-8. doi: 10.3748/wjg.v19.i44.7880.

引用本文的文献

1
Trends in Hospitalizations of Patients with Hepatitis C Virus in Poland between 2012 and 2022.2012年至2022年波兰丙型肝炎病毒患者住院情况趋势
J Clin Med. 2024 Sep 22;13(18):5618. doi: 10.3390/jcm13185618.
2
The Real-World Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C in Patients Active Malignancies.直接作用抗病毒药物用于患有活动性恶性肿瘤的慢性丙型肝炎患者的真实世界疗效和安全性
Cancers (Basel). 2024 Sep 9;16(17):3114. doi: 10.3390/cancers16173114.

本文引用的文献

1
Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023.2023年波兰丙型肝炎专家小组关于丙型肝炎治疗的建议。
Clin Exp Hepatol. 2023 Mar;9(1):1-8. doi: 10.5114/ceh.2023.125957. Epub 2023 Mar 24.
2
Hepatitis C: Standard of Treatment and What to Do for Global Elimination.丙型肝炎:治疗标准与全球消除策略。
Viruses. 2022 Feb 28;14(3):505. doi: 10.3390/v14030505.
3
Is elimination of HCV realistic by 2030: France.2030 年消除 HCV 是否现实:法国。
Liver Int. 2021 Jun;41 Suppl 1:45-49. doi: 10.1111/liv.14862.
4
Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020.丙型肝炎病毒消除途径的关键要素:来自美国肝病研究学会丙型肝炎特别兴趣小组2020年的经验教训
Hepatol Commun. 2021 May 3;5(6):911-922. doi: 10.1002/hep4.1731. eCollection 2021 Jun.
5
Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal.丙型肝炎病毒:德国目前迈向消除的步骤及实现2030年目标的障碍。
Health Sci Rep. 2021 Jun 4;4(2):e290. doi: 10.1002/hsr2.290. eCollection 2021 Jun.
6
Elimination of hepatitis C in Australia by 2030: a decade and counting.到2030年在澳大利亚消除丙型肝炎:十年倒计时。
Aust Prescr. 2021 Apr;44(2):36-37. doi: 10.18773/austprescr.2021.003. Epub 2021 Apr 1.
7
Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.直接作用抗病毒药物(DAAs)“治疗所有”策略对不同纤维化分期的日本慢性丙型肝炎基因 1 型患者的成本效益分析。
PLoS One. 2021 Apr 1;16(4):e0248748. doi: 10.1371/journal.pone.0248748. eCollection 2021.
8
Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study.加拿大安大略省慢性丙型肝炎病毒感染相关的医疗保健费用:一项回顾性队列研究。
CMAJ Open. 2021 Mar 8;9(1):E167-E174. doi: 10.9778/cmajo.20200162. Print 2021 Jan-Mar.
9
EASL recommendations on treatment of hepatitis C: Final update of the series.EASL 丙型肝炎治疗建议:系列的最终更新。
J Hepatol. 2020 Nov;73(5):1170-1218. doi: 10.1016/j.jhep.2020.08.018. Epub 2020 Sep 15.
10
Searching for the optimal population for hepatitis C virus screening in Poland.寻找波兰丙型肝炎病毒筛查的最佳人群。
Clin Exp Hepatol. 2020 Jun;6(2):74-76. doi: 10.5114/ceh.2020.94969. Epub 2020 Apr 30.